Crohn’s Disease & Mycobacterial Infections Kimberly Persley, MD October 19, 2005.

Slides:



Advertisements
Similar presentations
Inflammatory Bowel Disease: Overview
Advertisements

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Opportunistic Bacterial Infections in Inflammatory Bowel Disease By: Christina Philips.
The Microbiome: What’s the immune system got to do with it?
Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.
Nov GTX – A SHOT IN THE ARM, OR A COSTLY MISTAKE by PEER PRESSURE Cure’s Dilemma.
Resident Report Bronchiectasis Irreversibly dilated peripheral airways secondary to chronic inflammation from a variety of causes Pathogenesis.
Tolerance, autoimmunity and the pathogenesis of immune-mediated inflammatory diseases Abul K. Abbas UCSF.
Inflammatory Bowel Disease Kimberly Persley, MD Digestive Disease Associates of Dallas Presbyterian Hospital of Dallas.
Inflammatory Bowel Disease
DRUG TREATMENT OF INFLAMMATORY BOWEL DISEASE. Objectives Describe the mechanism of action, pharmacokinetics and adverse effects of drugs in IBD.
Hannover Medical School February 15 th 2010 The gut microbiota shapes intestinal immune response during health and disease Round and Mazmanian, Nature.
Ulcerative Colitis. Which of the following would not be associated with UC Toxic megacolon Granulomas Pseudopolyps Primary sclerosing cholangitis.
Evaluation of the genetic impact on inflammatory bowel disease Natalie Bibb Trainee Project KGC.
Immunotolerance Christoph Mueller
DAREDEVILS: Prajwal Acharya, Cristina Johnson, Julie David, Jen Masciovecchio, Yen Phan.
KRISTEN DOSTIE Alteration of Chemotaxis in the Gut of IBD Patients.
Dr. Angus Lee SET 1 General Surgery. Burrill Crohn, an American Gastroenterologist, with his 2 other colleagues first described “Terminal ileitis” in.
Inflammatory Bowel Disease Francisco A. Sylvester, MD Associate Professor of Pediatrics.
Aetiology and Pathology of Inflammatory Bowel Disease. Dr Bryan F Warren Consultant Gastrointestinal Pathologist, John Radcliffe Hospital, Oxford, UK M62.
Musketeers Course October The Mucosal Immune System The organization of the mucosal immune systemThe organization of the mucosal immune system The.
“Antibiotics and corticosteroids: Indications and approaches”
Crohn Disease : from gene to therapy
The Human Microbiome: PSC, IBD, and the Gut-Liver Axis
Modeling Crohn’s Disease. Crohn’s disease usually presents in early adulthood. Patients have a markedly reduced quality of life and a 5 to 7-fold increased.
The life history of T lymphocytes Precursors mature in the thymus Naïve CD4+ and CD8+ T cells enter the circulation Naïve T cells circulate through lymph.
Community Medicine V Dr. Mehrdad Askarian MD, MPH Professor of Community Medicine.
Immunological Disease of the Gastrointestinal Tract
Pathogenicity of Infectious Diseases. PATHOGENENVIRONMENT HOST DISEASE TRIAD Host-Parasite Interactions OTHER MICROBES Microbial Interactions.
GI tract infections in IBD: Detection and treatment of Clostridium difficile, CMV and enteric pathogens: Case studies David G. Binion, MD Bruce E. Sands,
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
Inflammatory Bowel Disease Crohn’s Disease And Ulcerative Colitis.
Ulcerative Colitis Rachel Gavin.
Effector T Cell Subsets, Cytokines
AUTOIMMUNITY- II Dr. Ashraf Abdelfatah Deyab Assistant Professor of Pathology Collage of Medicine, Majmaah University-
BY Mahsa Asadbeik In the Name of God. Introduction Signaling, Cellular Sources, and Biological Activities IL-17 cytokines and receptors family IL-17 in.
Environmental factors Dysregulated immune response
GI Pathophysiology Jaeyoung Chun, M.D. Pathophysiology
INTERNATIONAL SYMPOSIUM ON FUNDED BY PATIENTS' ORGANISATIONS
IMMUNE RESPONSE AT MUCOSAL SURFACES
Immunity in the Gut Andrew M. Platt, University of Glasgow, UK
Ulcerative colitis andTrichuris infection
Cumulative Probability of Developing Colon Cancer in UC Patients
Opiate use in patients with inflammatory bowel disease
Work disability in inflammatory bowel disease
Inflamm Intest Dis 2016;1: DOI: /
Mersin University TURKEY
Inflammatory Bowel Disease
Volume 380, Issue 9853, Pages (November 2012)
Oral Vancomycin as a Therapeutic Option for PSC
Microbial Influences in Inflammatory Bowel Diseases
Gut Microbiota: Mining for Therapeutic Potential
Daniel A. Peterson, Daniel N. Frank, Norman R. Pace, Jeffrey I. Gordon 
Benoit Chassaing, Arlette Darfeuille–Michaud  Gastroenterology 
Inflammatory Bowel Disease as a Model for Translating the Microbiome
Pathogenic Escherichia coli in inflammatory bowel diseases
Intestinal Inflammation and Cancer
Volume 139, Issue 6, Pages (December 2010)
Mechanisms of Disease: Inflammatory Bowel Diseases
Volume 127, Issue 1, Pages (July 2004)
Translating Inflammatory Bowel Disease Research into Clinical Medicine
Drivers of chronic rhinosinusitis: Inflammation versus infection
Homeostasis and Inflammation in the Intestine
Figure 2 Lifelong influences on the gut microbiome from
Daniel A. Peterson, Daniel N. Frank, Norman R. Pace, Jeffrey I. Gordon 
Introduction of Inflammatory bowel disease-Crohn’s disease
Route Connection: Mouth to Intestine in Colitis
Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases  Louis J. Cohen, Judy H. Cho,
Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.
Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.
Presentation transcript:

Crohn’s Disease & Mycobacterial Infections Kimberly Persley, MD October 19, 2005

Outline Epidemiology Presumed Etiopathogenesis Antibiotic Therapy Mycobacteria and IBD

IBD Spectrum Ulcerative colitis Crohn’s Disease Indeterminant colitis

Normal Intestine Vs. IBD Environmental triggers (infection, bacterial products) Moderately inflamed Failure to down- regulate Chronic uncontrolled inflammation = IBD Down-regulate Normal gut controlled inflammation Normal gut controlled inflammation

Evidence of Genetic Influence Prevalence varies among different populations risk in increased among first degree relatives greater concordance among monozygotic than diazygotic twins identification of “susceptibility genes” (NOD2/CARD 15)

NOD2/CARD15 Intracellular pattern recognition receptors Participates in host defense against microbial pathogens –recognition or molecular pattern present of pathogens –activation of nuclear factor kB –induction and secretion of pro/anti- inflammatory cytokines and chemokines –induction of antimicrobial pathways

Defective NOD2 Function Ineffective clearance of intracellular MAP infection Decrease in defensin secretion –permits increased mucosal adherence and epithelial invasion of ingested organisms

IBD Treatment Pyramid 5-ASA Antibiotics Steroids Immunomodulators Biologics severityseverity

Antibiotics Lack of well-designed, placebo-controlled trials Large “Antibiotic” underground Ciprofloxacin and Metronidazole are the two most widely studied abx Rifaximin may have a promising role in CD Antimycobacterial drugs results are inconclusive

Histology Normal SB histology Crohn’s Disease

Infection and IBD Histopathology NOD2 mutations High bacterial concentrations in the TI and colon are preferentially involved in IBD Altered composition of commensal enteric bacteria Clinical improvement with antibiotics

Detection of MAP from Mucosal Biopsies Sardinia 1.6 million people 3.5 million sheep and MAP infection endemic determine the proportion of MAP infected people Sechi, Leonard et al. AJG 2005:100:1529

Prevalence of MAP Germany 100 CD, 100 UC and 100 normals IS900 PCR in resected bowel specimens Autschback F. et al. Gut 2005;54:944

Culture of MAP in CD University of Florida 52 patients –28 CD –9 UC –15 Controls presence of viable MAP in peripheral blood of pts with CD Nasser S. et al. Lancet 2004;364:1039

Does MAP cause Crohn’s disease? I just don’t KNOW!!! MAP infection may cause CD in a subset of patients MAP colonize ulcerated mucosa of CD but not initiate or perpetuate intestinal inflammation